Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype.
Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, Principe P, Twelves C, Verweij J, McLeod HL. Sparreboom A, et al. Among authors: principe p. Clin Pharmacol Ther. 2004 Jul;76(1):38-44. doi: 10.1016/j.clpt.2004.03.003. Clin Pharmacol Ther. 2004. PMID: 15229462
A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours.
Scott L, Soepenberg O, Verweij J, de Jonge MJ, Th Planting AS, McGovern D, Principe P, Obach R, Twelves C. Scott L, et al. Among authors: principe p. Ann Oncol. 2007 Mar;18(3):569-75. doi: 10.1093/annonc/mdl439. Ann Oncol. 2007. PMID: 17322542 Free article. Clinical Trial.
Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF, Garrido MJ, Segura C, Cendrós JM, Principe P, Peraire C, Obach R. Trocòniz IF, et al. Among authors: principe p. Cancer Chemother Pharmacol. 2006 Jun;57(6):727-35. doi: 10.1007/s00280-005-0112-6. Epub 2005 Oct 28. Cancer Chemother Pharmacol. 2006. PMID: 16261364 Clinical Trial.
Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors.
Trocóniz IF, Cendrós JM, Soto E, Pruñonosa J, Perez-Mayoral A, Peraire C, Principe P, Delavault P, Cvitkovic F, Lesimple T, Obach R. Trocóniz IF, et al. Among authors: principe p. Cancer Chemother Pharmacol. 2012 Aug;70(2):239-50. doi: 10.1007/s00280-012-1906-y. Epub 2012 Jun 15. Cancer Chemother Pharmacol. 2012. PMID: 22699813 Clinical Trial.
69 results